scholarly journals Pulse versus daily oral Alfacalcidol treatment of secondary hyperparathyroidism in hemodialysis patients: a randomized controlled trial

2018 ◽  
Vol Volume 11 ◽  
pp. 25-32 ◽  
Author(s):  
Osama Sawalmeh ◽  
Shaheed Moala ◽  
Zakaria Hamdan ◽  
Huda Masri ◽  
Khubaib Ayoub ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Secondary Hyperparathyroidism ◽  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Randomized Controlled

scholarly journals Effects of Denosumab and Alendronate on Bone Health and Vascular Function in Hemodialysis Patients: A Randomized, Controlled Trial

2019 ◽  
Vol 34 (6) ◽  
pp. 1014-1024 ◽  
Author(s):  
Ken Iseri ◽  
Makoto Watanabe ◽  
Hisako Yoshikawa ◽  
Hisao Mitsui ◽  
Teruhiko Endo ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Bone Health ◽  
Vascular Function ◽  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Randomized Controlled

scholarly journals Hypertension in hemodialysis patients treated with atenolol or lisinopril: a randomized controlled trial

2014 ◽  
Vol 29 (3) ◽  
pp. 672-681 ◽  
Author(s):  
Rajiv Agarwal ◽  
Arjun D. Sinha ◽  
Maria K. Pappas ◽  
Terri N. Abraham ◽  
Getachew G. Tegegne
Keyword(s):  
Randomized Controlled Trial ◽  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Randomized Controlled

scholarly journals Paricalcitol Versus Ergocalciferol for Secondary Hyperparathyroidism in CKD Stages 3 and 4: A Randomized Controlled Trial

2012 ◽  
Vol 59 (1) ◽  
pp. 58-66 ◽  
Author(s):  
Csaba P. Kovesdy ◽  
Jun L. Lu ◽  
Sandra M. Malakauskas ◽  
Dennis L. Andress ◽  
Kamyar Kalantar-Zadeh ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Secondary Hyperparathyroidism ◽  
Controlled Trial ◽  
Randomized Controlled

scholarly journals A pharmacist‐managed dosing algorithm for darbepoetin alfa and iron sucrose in hemodialysis patients: A randomized, controlled trial

2020 ◽  
Vol 8 (4) ◽  
Author(s):  
Francisca Johanna Oever ◽  
Carolien F. M. Heetman‐Meijer ◽  
Erwin Birnie ◽  
Erwin C. Vasbinder ◽  
Eleonora L. Swart ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Darbepoetin Alfa ◽  
Controlled Trial ◽  
Hemodialysis Patients ◽  
Iron Sucrose ◽  
Randomized Controlled ◽  
Dosing Algorithm

Urokinase-Containing Locking Solution in the Prevention of Dialysis Catheter Dysfunction: A Double Blind Randomized Controlled Trial

2017 ◽  
Vol 18 (5) ◽  
pp. 436-442 ◽  
Author(s):  
Florence Bonkain ◽  
Freya Van Hulle ◽  
Peter Janssens ◽  
Concetta Catalano ◽  
Mandelina Allamani ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Incidence Rate ◽  
Controlled Trial ◽  
Recombinant Tissue Plasminogen Activator ◽  
Hemodialysis Patients ◽  
Control Group ◽  
Double Blind ◽  
Systemic Thrombolysis ◽  
Randomized Controlled ◽  
History Of

Introduction The prophylactic use of recombinant tissue plasminogen activator once weekly reduces the incidence rate of tunneled cuffed catheter (TCC) malfunction and bacteremia as compared to the exclusive use of heparin as locking solution. Restricting the use of prophylactic thrombolytic agents to patients with a history of thrombotic TCC malfunction could be more cost effective. We conduct a multicenter, double-blind, randomized controlled trial and test the hypothesis that weekly use of urokinase lock will reduce the incidence of thrombotic malfunction by 50% in prevalent hemodialysis patients with a history of thrombotic malfunction. Methods Patients with a history of at least two separate TCC thrombotic dysfunctions treated with urokinase lock during the 6 months preceding inclusion are recruited in eight Belgian dialysis units. Patients are randomized in two groups: the control group receiving Taurolock™-HEP500 (heparin 500 IU/mL, taurolidine, citrate 4%) after each hemodialysis session and the treatment group receiving Taurolock-U 25,000 (urokinase 25,000, taurolidine, citrate 4%) once a week and the standard Taurolock-HEP500 at the end of the two others sessions. The primary outcome is the incidence rate of TCC thrombotic dysfunction defined by the use of urokinase. The secondary outcomes are the incidence rate of TCC removal and systemic thrombolysis. For the study, both patients and healthcare staff are blinded to treatment allocation. Conclusions The present trial is the first to investigate the effect of Taurolock-U 25,000 catheter lock once a week as secondary prevention in hemodialysis patients with the highest risk of TCC-related thrombotic dysfunction. Trial Registration ClinicalTrials.gov Identifier: NCT02036255

Sign in / Sign up

Export Citation Format

Share Document